Brain, Behavior, & Immunity - Health
November 1, 2021
N. Nikkheslat
67 citations
Major depressive disorder (MDD) is a common psychiatric disorder with multifactorial aetiology and complex pathophysiology. Despite availability of various pharmacological and non-pharmacological therapeutic strategies, treatment resistant depression (TRD) remains a significant challenge with specific concern for those patients with severe depressive symptoms in particular suicidal ideations...
Journal of Psychiatric Practice
November 1, 2021
Amir Garakani
Treatment-resistant depression (TRD) may be responsive to interventions beyond antidepressants including brain stimulation such as electroconvulsive therapy (ECT) or to ketamine or esketamine, the latter of which is approved for TRD in an intranasal form. The 3 cases presented in this issue deal with an array of clinical considerations in treating patients with TRD, including the use of ECT in...
Journal of diabetes and metabolic disorders
October 31, 2021
Wojujutari Kenni Ajele, Teslim Alabi Oladejo, Abimbola A Akanni et al.
Purposes: The study examined the mediation moderated effects of spiritual intelligence and mindfulness on the relationship between emotional dysregulation, depression and mental well-being. It also investigated the mediating effects of mindfulness on the relationship between spiritual intelligence and mental well-being in persons with diabetes. Methods: A cross-sectional survey was carried out...
BMC Psychiatry
October 31, 2021
Nagahide Takahashi, Aya Yamada, Ayako Shiraishi et al.
56 citations
Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD). Efficacy, safety, and tolerability of esketamine nasal spray in Japanese patients with TRD needs to be assessed. Methods This Phase 2b, randomized, double-blind (DB), placebo-controlled...
European Journal of Clinical Pharmacology
October 27, 2021
T. Lima, M. B. Visacri, P. M. Aguiar
38 citations
To summarize the evidence of efficacy and safety of the use of ketamine and esketamine for depression. A literature search was performed in Medline, the Cochrane Library, LILACS, and CRD until November 2020. We included systematic reviews with meta-analyses of randomized controlled trials on the use of ketamine and esketamine in adult patients with depression. Two authors independently...
Translational Psychiatry
October 23, 2021
Fangfang Chen, Xueyu Lv, Jiliang Fang et al.
Mindfulness-based interventions such as meditation have increasingly been utilized for the treatment of psychological disorders and have been shown to be effective in the treatment of depression and relapse prevention. However, it remains largely unclear the neural mechanism of the therapeutic effects of meditation among depressed individuals. In this study, we investigated how body-mind...
The Journal of Laryngology and Otology
October 22, 2021
M. Hicks, L. A. Braden, E. M. Walsh et al.
Abstract Background Burnout, anxiety and depression are commonly reported among surgical residents and faculty members. Resident training programmes are encouraged to implement structured wellness initiatives, to address emotional stress. Methods Thirty otolaryngology residents and faculty members were invited to participate in this prospective pilot trial. Participants were randomised to...
Healthcare
October 21, 2021
Paola Lavín, Rim Nazar, Marouane Nassim et al.
7 citations
(1) Objective: to determine if a brief mindfulness intervention (BMI) and a health education program (HEP) could improve measures of insomnia in patients undergoing hemodialysis. (2) Methods: this was a planned secondary analysis of a randomized controlled trial of BMI vs. HEP for hemodialysis patients with depression and/or anxiety symptoms. The primary outcome for the analysis was the Athens...
Frontiers in Psychiatry
October 18, 2021
Alina Wilkowska, Mariusz S. Wiglusz, Maria Gałuszko‐węgielnik et al.
35 citations
Anhedonia constitutes one of the main symptoms of depressive episode. It correlates with suicidality and significantly effects the quality of patient's lives. Available treatments are not sufficient against this group of symptoms. Ketamine is a novel, rapid acting strategy for treatment resistant depression. Here we report the change in symptoms of anhedonia measured by Snaith-Hamilton Pleasure...
Open Access Indonesian Journal of Medical Reviews
October 15, 2021
Lovina Lovina
Depressive disorder is still a significant problem in several developed countriesand is morbidity caused by mental disorders. With the development of science,now discovered the unique pharmacodynamic properties of ketamine, which isused as an antidepressant. As we know in clinical practice, ketamine is used foranaesthesia, analgesia, sedation, and chronic pain management....